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generic risperidone, although there were prescribing restrictions 
for long-acting injectable risperidone in Austria and Belgium. As a 
result, no change in its utilization after generics reimbursed. Overall, 
high utilization of generic versus originator risperidone once avail-
able. Appreciable reduction in the price of generic risperidone once 
it became available limited the extent of any subsequent increase in 
AAP expenditure despite increasing utilization.
Conclusion: No apparent effectiveness or safety problems with 
generic risperidone. Authorities cannot rely on a spillover effect from 
other disease areas to change physician prescribing habits, exacer-
bated on this occasion by the need to tailor treatment approaches 
with different AAPs having different mechanisms of action and 
appreciable variability in their effectiveness and side-effects between 
patients Consequently, specific demand-side measures are needed to 
encourage the prescribing of generic AAPs first line where appropri-
ate, exacerbated by the complexity of these disease areas. Likely 
in any event that there will be limited influence of any measures 
in changing subsequent physician prescribing habits when manag-
ing patients with schizophrenia or BPD compared with acid-related 
stomach disorders or hypercholesterolemia as a greater need to tailor 
treatments. Generally no specific measures planned by these authori-
ties to influence future prescribing habits with further generic AAPs 
becoming available.
Financial Source: Study part funded by a grant from the Karolinska 
Institutet. Majority of authors employed by health authorities or are 
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Introduction: Antidepressive drug venlafaxine belongs to the seroto-
nine and norepinephrine reuptake inhibitors. It is primary metabo-
lized by CYP2D6 to its active metabolite O-desmethylvenlafaxine 
and by CYP3A4 to N-desmethylvenlafaxine. The range 0.3-5.2 for 
O-desmethylvenlafaxine/venlafaxine ratio was estimated for exten-
sive and intermediate metabolizers.
Patients (or Materials) and Methods: There is described intoxication 
of woman (41 years) treated by combination therapy venlafaxine 
150 mg/d, mianserine 60 mg/d, clonazepam 1 mg/d, and olanzapine 
10 mg/d. TDM of these substances was provided using LC-MS/MS 
method to estimate phenotype of venlafaxine and to compare with 
genotype.
Results: On admission, toxic plasma level of venlafaxine was 
found (2638 ng/mL) and after reduction of the dose to 75 mg/d 
plasma level was estimated in therapeutic range (364 ng/mL). The 
ratio O-desmethylvenlafaxine/venlafaxine was estimated between 
0.005 and 0.016 showing poor metabolizator. Genetic examina-
tion detected homozygotes deletion of the gene CYP2D6 *5/*5 
and explained phenotype. Plasma level of olanazapine was found 
in therapeutic range, plasma level of clonazepam was found below 
therapeutic range.
Conclusion: The ratio of the metabolite to the parent substance (phe-
notype) allows us to detect any deviation in the metabolism of drugs 
which can be subsequently explained by determination of genotype. 
Therapeutic drug monitoring contributes to the optimalization of 
pharmacotherapy in the case of psychotropic drugs.
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Introduction: Alzheimer’s disease is a neurodegenerative disorder 
associated with depletion of acetylcholine in neuronal terminals with 
increased oxidative stress in cells resulting in neuroinflammation. 
Inhibiting acetylcholine esterase (AchE) increases the concentration of 
neuronal acetylcholine. Further xanthine oxidase (XO) is an important 
source of free radicals and plays an important role in oxidative stress 
associated with neuroinflammation. Thus, a dual acting inhibitor of 
AchE & XO can be a good candidate for the treatment of neurodegen-
erative disorders like Alzheimer’s. The aim of this study is to explore the 
inhibitory potential of 4-methyl esculetin against both AchE and XO.
Patients (or Materials) and Methods: The X-ray crystal structures of 
rivastigmine bound to acetylcholinesterase (AChE) (PDB 1GQR) and 
quercetin bound to xanthine oxidase (XO) (PBD 3NVY) were obtained 
from the Protein Data Bank. The proteins were prepared for the dock-
ing studies with the Protein Preparation Wizard in the Schrödinger Suite 
2012 (Schrödinger LLC, USA). The ligand 4-methyl esculetin (4-ME) 
was docked into the target proteins AhcE and XO and binding poses 
ranked by Glide Score (SP). The inhibitory activity of 4-ME towards 
AchE was measured by an in vitro assay using rat brain AchE, and inhi-
bition of XO was done using crude XO obtained from rat liver tissue.
Results: The docking studies revealed that 4-methyl esculetin binds 
in a similar fashion to both AChE and XO and makes identical inter-
actions as the native ligands (rivastigmine for AchE & quercetin for 
XO). The Glide Score for 4-methyl esculetin (–6.97 for AchE and 
–7.78 for XO) also does not differ significantly in both targets; hence, 
it can be said with confidence that 4-ME should exhibit comparable 
potency towards the 2 protein targets. This is well substantiated by 
in vitro enzyme assays that confirmed the equal inhibitory properties 
of 4-ME towards both the target viz. AchE and XO. Kinetic studies 
showed that 4-ME acts as a competitive inhibitor against XO while 
exhibiting mixed type inhibition toward AchE.
Conclusion: The results of the present study indicate that a combi-
nation of both AchE and XO inhibitory properties for 4-ME could 
make it a useful asset in the management of Alzheimer’s disease.
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Introduction: Aluminium is a potent neurotoxin and has been associ-
ated with Alzheimer’s disease (AD). Prolonged aluminium exposure 
induces oxidative stress and contributes to the development of neu-
rodegeneration. Current treatment modalities for AD provide only 
symptomatic relief, thus necessitating the development of new drugs 
with multiple targeting strategies. The aim of the study was to dem-
onstrate the protective effect of chronic administration of 4-methyl-
esculetin (4-ME) against aluminium-induced cognitive dysfunction 
and oxidative damage in rats.
Patients (or Materials) and Methods: Wistar rats (180–200 g) were 
divided into 6 groups (n = 6). Group I was the control group and 
group II received aluminium chloride (100 mg/kg PO) for a period 
of 42 days. Group III and IV received 4-ME (50 and 100 mg/kg PO) 
daily 1 hour before aluminium chloride (100 mg/kg PO) for 42 days 
while groups V and VI received only 4-ME (50 and 100 mg/kg PO) 
daily for 42 days. On the 21st and 42nd day, behavioral studies 
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were done to evaluate memory (Morris water maze and elevated 
plus maze task), exploratory behavior and anxiety (Open field test) 
and locomotion (actophotometer). The rats were sacrificed on day 
43 after the last behavioral test. Markers for cellular oxidative stress, 
mitochondrial oxidative parameters, acetylcholine esterase activity, 
and aluminum concentration in the brain tissue were assessed.
Results: Chronic aluminium chloride treatment caused cognitive 
dysfunction (as shown by behavioral tasks) and mitochondrial 
and cellular oxidative damage compared with the vehicle-treated 
control group. Besides, aluminium chloride treatment significantly 
increased acetyl cholinesterase activity and aluminum concentration 
in the brain compared with control. Coadministration of 4-ME sig-
nificantly improved cognitive performance and attenuated cellular 
and mitochondrial oxidative damage, acetyl cholinesterase activity 
and aluminum concentration in aluminium-treated rats. Only 4-ME 
treatment for 42 days did not alter the studied parameters in rats.
Conclusion: Results of the study demonstrate neuroprotective poten-
tial of 4-ME against aluminium chloride–induced neurodegeneration. 
Thus, 4-ME can be a promising candidate in the management of 
Alzheimer’s disease.
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Introduction: Studies have suggested neurotoxic effects of amyloid 
β protein and oxidative stress in Alzheimer’s disease. In the present 
study, we have analyzed the effect of a diet rich in figs for 1 year on 
behavior abnormalities in AppSw 2576 AD transgenic mouse model.
Patients (or Materials) and Methods: The experimental groups of 
APP-transgenic mice from the age of 4 months were fed custom-mix 
diets (pellets) containing 4% figs. These experimental and control mice 
behavior status were examined every 3 months for a period of 1 year 
by Morris water maze test (for spatial memory and learning ability), 
T maze test (for position discrimination learning ability), rota rod test 
(for psychomotor coordination), elevated plus maze test and open field 
(for anxiety-related behavior), and open field test to analyze the effect 
of fig-rich diet rich on memory, anxiety, and learning skills.
Results: APPsw/Tg2576 mice fed with the control diet showed a 
trend of memory deficit, anxiety-related behavior, and severe impair-
ment in spatial learning ability, position discrimination learning abil-
ity and motor coordination compared with the wild-type mice on the 
same diet. The fig-rich diet fed AD mice showed significant behavior 
improvement when compared with AD Tg mice.
Conclusion: Our results suggest that long term supplementation of 
fig in the diet might have the beneficial effect in reducing the risk, 
delaying the onset or slowing the progression of Alzheimer’s disease 
and also our results suggest that further studies are needed to validate 
and determine the mechanism of action of these fruits against AD.
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Introduction: To determine the prevalence of drug-induced long QT 
at admission to a public psychiatric hospital and document associated 
factors in a cross-sectional approach.
Patients (or Materials) and Methods: All ECG recordings over a 
5-year period were reviewed for drug-induced long QT (QTc ≥ 500 
ms; certain or probable drug imputability) and associated conditions. 
Patients with drug-induced long QT (n = 62) were compared with a 
sample of patients with normal ECG (n = 143).
Results: Among 6790 inpatients, 27.3% had abnormal ECG, 1.6% 
had long QT, and 0.9% were detected as drug-induced long QT 
cases. Sudden cardiac death was recorded in 5 patients and torsades 
de pointes in 7 other patients. Drug-induced long QT patients had 
significantly higher frequencies of hypokalemia (19.4% vs 5.6%; P = 
0.004), hepatitis C virus infection (41.9% vs 9.8%; P < 0.001), HIV 
infection (24.2% vs 6.3%; P = 0.001), and abnormal T-wave mor-
phology (35.5% vs 15.4%; P = 0.003). Haloperidol, sertindole, clo-
tiapine, phenothiazines, fluoxetine, (es-) citalopram, and methadone 
were significantly more frequent in drug-induced long QT patients. 
After adjustment for hypokalemia, hepatitis C virus infection, HIV 
infection, and abnormal T-wave morphology, effects of haloperidol, 
clotiapine, phenothiazines, and (es-)citalopram remained statistically 
significant. Receiver operating characteristic curve analysis based on 
the number of endorsed factors per patient indicated that 85.5% of 
drug-induced long QT patients had ≥ 2 factors, whereas 81.1% of 
normal ECG patients had < 2 factors.
Conclusion: Drug-induced long QT and arrhythmia propensity sub-
stantially increase when specific psychotropic drugs are administered 
to patients with hypokalemia, abnormal T-wave morphology, hepa-
titis C virus infection, and HIV infection.
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Introduction: Hepatic metabolism of clomipramine (C) consists of 
demethylation into the active metabolite desmethylclomipramine 
(DC) by CYP2C19 and CYP3A4, and hydroxylation of the par-
ent drug and the metabolite catalyzed by CYP2D6. CYP2D,6 and 
CYP2C19 are characterized by genetically determined polymor-
phisms. The influence of CYP2D6 and CYP2C19 polymorphisms on 
C and DC plasma concentrations and on occurrence of adverse effects 
is well described, but its role on clinical outcome is more anecdotal.
Patients (or Materials) and Methods: We report the case of a 40-year-
old woman with severe recurrent depressive disorder, history of 
several suicide attempts, borderline personality disorder, and fibro-
myalgia, who was admitted in Geneva Psychiatric Hospital during 6 
months for her fourth suicide attempt. Oral treatments with dulox-
etine (30 mg/d), escitalopram (30 mg/d), venlafaxine (225 mg/d), and 
mirtazapine (30 mg/d) were successively tried but were considered 
ineffective. A significant improvement, observed by the caregivers 
and the patient herself, was eventually obtained with intravenous (IV) 
clomipramine (50 mg/d). The patient returned home with oral clomi-
pramine (112.5 mg/d), olanzapine (5 mg/d), flurazepam (15 mg/d), 
